Assyro AI

FDA Orange Book · active-ingredient family

Prednisolone acetate; sulfacetamide sodium

Prednisolone acetate; sulfacetamide sodium is approved as 2 brand and 9 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:BLEPHAMIDE · NDA 012813

2

Brand (NDA)

9

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · ointment, suspension, suspension/drops

ProductApplicantApplicationTEApproved
BLEPHAMIDERLDALLERGANNDA 012813Approved Prior to Jan 1, 1982
METIMYD×2SCHERINGNDA 010210Sep 09, 1984

Generic (ANDA) products (9)

ProductApplicantApplicationTEApproved
CETAPREDALCONANDA 087771Aug 06, 1993
BLEPHAMIDE S.O.P.ALLERGANANDA 087748Dec 03, 1986
PREDSULFAIR IIPHARMAFAIRANDA 088837Dec 24, 1985
VASOCIDINNOVARTISANDA 088791Oct 05, 1984
PREDAMIDEEPIC PHARMA LLCANDA 088059Jul 29, 1983
PREDSULFAIRPHARMAFAIRANDA 088007Apr 19, 1983
PREDSULFAIRPHARMAFAIRANDA 088032Apr 15, 1983
SULPHRINBAUSCH AND LOMBANDA 088089Dec 28, 1982
ISOPTO CETAPREDALCONANDA 087547Approved Prior to Jan 1, 1982

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Prednisolone acetate; sulfacetamide sodium — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.